


THE REGIONAL EMERGENCY MEDICAL SERVICES COUNCIL OF NEW YORK CITY, INC.

	<h2>NYC REMAC</h2>		
	Advisory No.	1999-02	
	Title:	Unavailability of Bretylium Tosylate	
	Date:	November 23, 1999	
	Supersedes:	N/A	Page:

An increasing number of ALS agencies in the New York City Region are unable to obtain Bretylium Tosylate to replace used or expired vials and pre-filled syringes. This is due to the inability of manufacturers of the medication to obtain an essential raw material used in the production of Bretylium Tosylate.

Regarding REMAC Prehospital Treatment Protocols #503-B and 603-B (Ventricular Fibrillation / Pulseless Ventricular Tachycardia): Until Bretylium Tosylate supplies are restored providers may omit the administration of Bretylium Tosylate and subsequent defibrillation in the above protocols.

Attached you will find a copy of the statement from the American Heart Association on Bretylium Tosylate.